JPS56500655A - - Google Patents

Info

Publication number
JPS56500655A
JPS56500655A JP50123580A JP50123580A JPS56500655A JP S56500655 A JPS56500655 A JP S56500655A JP 50123580 A JP50123580 A JP 50123580A JP 50123580 A JP50123580 A JP 50123580A JP S56500655 A JPS56500655 A JP S56500655A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP50123580A
Other languages
Japanese (ja)
Other versions
JPH0135840B2 (enExample
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPS56500655A publication Critical patent/JPS56500655A/ja
Publication of JPH0135840B2 publication Critical patent/JPH0135840B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/18—Thymus derived hormone or factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP55501235A 1979-05-15 1980-05-14 Expired JPH0135840B2 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792919592 DE2919592A1 (de) 1979-05-15 1979-05-15 Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon

Publications (2)

Publication Number Publication Date
JPS56500655A true JPS56500655A (enExample) 1981-05-14
JPH0135840B2 JPH0135840B2 (enExample) 1989-07-27

Family

ID=6070778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP55501235A Expired JPH0135840B2 (enExample) 1979-05-15 1980-05-14

Country Status (8)

Country Link
US (2) US4353821A (enExample)
EP (1) EP0028627B1 (enExample)
JP (1) JPH0135840B2 (enExample)
CH (1) CH649089A5 (enExample)
DE (1) DE2919592A1 (enExample)
GB (1) GB2065662B (enExample)
NL (1) NL8020195A (enExample)
WO (1) WO1980002560A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0033384B1 (de) * 1980-01-18 1984-02-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thymosin-alpha-1-Fragmente enthaltende Arzneimittel mit immunstimulierender Wirkung, und Thymosin-alpha-1-Fragmente
DE3137231A1 (de) * 1981-09-18 1983-04-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Bis-thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-verbindungen
US4497801A (en) * 1982-09-17 1985-02-05 Fujisawa Pharmaceutical Co., Ltd. New peptides, process for preparation thereof and use thereof
US4581168A (en) * 1983-02-21 1986-04-08 Sanofi Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
US4517119A (en) * 1983-04-04 1985-05-14 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4504415A (en) * 1983-04-04 1985-03-12 Hoffman-La Roche Inc. Synthesis of thymosin α1 and desacetyl thymosin α1
FR2551088B1 (enExample) * 1983-08-29 1985-12-06 Pasteur Institut
ZA873215B (en) * 1986-05-19 1987-10-28 Viral Technologies Inc. Htlv-iii/lav virus related peptides,antibodies to the peptides,vaccines,passive and active immunization against aids virus and diagnostic test for the serological detection of aids virus
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5807830A (en) * 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
US5811399A (en) * 1988-12-14 1998-09-22 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants
US5770576A (en) * 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
US6066622A (en) 1991-10-28 2000-05-23 Cytran, Inc. Immunomodulating peptides and methods of use
CN1058500C (zh) * 1993-02-03 2000-11-15 施塞克龙药品公司 胸腺素α－1衍生物
WO1994020063A2 (en) * 1993-03-04 1994-09-15 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US6262230B1 (en) * 1994-01-28 2001-07-17 Sciclone Pharmaceuticals Inc. Analogs of thymosin α1
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
AU2001268326A1 (en) * 2000-06-14 2001-12-24 Chanda Zaveri Peptides with physiological activity
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
JP2004521867A (ja) 2000-10-27 2004-07-22 イミュノ−アールエックス， インコーポレイテッド 免疫抑制された患者のためのワクチン免疫療法
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20050020495A1 (en) * 2001-10-24 2005-01-27 Martins Eduardo Bruno Guimaraes Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
NZ532863A (en) * 2001-10-26 2006-07-28 Rhode Island Hospital Thymosin augmentation of genetic immunization for the treatment of hepatitis C
WO2003035004A2 (en) * 2001-10-26 2003-05-01 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
ATE511852T1 (de) * 2002-11-25 2011-06-15 Sciclone Pharmaceuticals Inc Verfahren zum schutz vor strahlungsschäden unter verwendung von alpha-thymosin
UA80870C2 (en) * 2003-03-28 2007-11-12 Sciclone Pharmaceuticals Inc Method for treatment or prevention of aspergillus infections with thymosin alpha 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US20060246057A1 (en) * 2003-07-18 2006-11-02 Regenerx Biopharmaceuticals, Inc Treatment or prevention of damage due to radiation exposure
JP5563472B2 (ja) 2007-11-28 2014-07-30 アイ アール エックス セーラピューティクス， インコーポレイテッド 免疫学的効果を増大させる方法
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
EP2510106B1 (en) 2009-12-08 2018-02-14 IRX Therapeutics, Inc. Method of reversing immune suppression of langerhans cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53137914A (en) * 1977-04-22 1978-12-01 Hoffmann La Roche Thymocine alpha1 or asn2 homologue thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH633258A5 (en) * 1976-10-28 1982-11-30 Hoffmann La Roche Process for preparing thymosin alpha 1
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2830442A1 (de) * 1978-07-11 1980-01-24 Max Planck Gesellschaft Verfahren zur herstellung von polypeptiden

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53137914A (en) * 1977-04-22 1978-12-01 Hoffmann La Roche Thymocine alpha1 or asn2 homologue thereof

Also Published As

Publication number Publication date
DE2919592A1 (de) 1981-01-15
US4466918A (en) 1984-08-21
NL8020195A (nl) 1981-02-27
WO1980002560A1 (fr) 1980-11-27
US4353821A (en) 1982-10-12
EP0028627B1 (de) 1984-05-09
JPH0135840B2 (enExample) 1989-07-27
GB2065662A (en) 1981-07-01
CH649089A5 (de) 1985-04-30
DE2919592C2 (enExample) 1992-01-16
EP0028627A1 (de) 1981-05-20
GB2065662B (en) 1983-03-30

Similar Documents

Publication Publication Date Title
FR2448488B1 (enExample)
FR2449872B1 (enExample)
FR2446822B1 (enExample)
JPS56500655A (enExample)
BR8002583A (enExample)
BR8006808A (enExample)
DE3050315A1 (enExample)
FR2449742B1 (enExample)
FR2446005B1 (enExample)
FR2445916B1 (enExample)
FR2449613B1 (enExample)
FR2449610B1 (enExample)
FR2448129B1 (enExample)
FR2448602B1 (enExample)
FR2447151B1 (enExample)
FR2448358B3 (enExample)
FR2447654B1 (enExample)
FR2446770B1 (enExample)
FR2445734B1 (enExample)
FR2447400B2 (enExample)
FR2448157B2 (enExample)
BR5901094U (enExample)
AU79918S (enExample)
AU80228S (enExample)
BG28678A1 (enExample)